A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes
Public ClinicalTrials.gov record NCT07881887. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Randomized, Participant- and Investigator-Blinded, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Dose Regimens of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight with or without Type 2 Diabetes. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration. Participation in the study will last between approximately 53 to 89 weeks. For each participant (excluding those in Part B), the study will include between 5 and 7 stays in the Clinical Research Unit (CRU), each stay lasting between approximately 8 and 10 nights.
Study identification
- NCT ID
- NCT07881887
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 617 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2026 (Estimated)
- Primary completion
- Mar 2029 (Estimated)
- Completion
- Mar 2029 (Estimated)
- Last update posted
- Oct 20, 2026
2026 – 2029
United States locations
- U.S. sites
- 11
- U.S. states
- 6
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| CenExel ACT | Anaheim | California | 92801 | — |
| Collaborative Neuroscience Network - CNS | Los Alamitos | California | 90720 | — |
| Diablo Clinical Research, Inc. | Walnut Creek | California | 94598 | — |
| Fortrea Clinical Research Unit | Daytona Beach | Florida | 32117 | — |
| Advanced Pharma CR, LLC | Miami | Florida | 33417 | — |
| Clinical Site Partners, LLC DBA CSP Orlando | Winter Park | Florida | 32789 | — |
| CenExel iResearch, LLC | Decatur | Georgia | 30030 | — |
| CenExel-HRI | Marlton | New Jersey | 08053 | — |
| Ohio Clinical Trials | Columbus | Ohio | 43212 | — |
| Fortrea Clinical Research Unit | Dallas | Texas | 75247 | — |
| Worldwide Clinical Trials, Inc. | San Antonio | Texas | 78217 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07881887, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 20, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07881887 live on ClinicalTrials.gov.